Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

Ventripoint's VMS+(TM) 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential

Ventripoint Wins Gold Edison Award But Cash Burn and Dilution Risks Persist

Executive Summary
  • Ventripoint Diagnostics Ltd. received a Gold Medal at the 2026 Edison Awards in the Precision Health Technologies sub-category for its VMS+™ 4.0 technology.
  • The award validates the platform's ability to transform standard 2D echocardiograms into accurate 3D heart models comparable to cardiac MRI at lower cost and time.
  • Technology is already clinically deployed in major hospitals across Canada, the United States, the United Kingdom, and Europe.
  • CEO Hugh MacNaught stated the award affirms the platform has moved beyond promise into real-world impact with room for growth as adoption accelerates.
  • This follows a series of partnership announcements including Costa Rica (Montecristo Group), Indigenous communities in Canada (First Light Health/Nisga'a Valley), and Northern California (LG Consulting Solutions).
Material Impact
  • The Edison Award is a reputational milestone but does not constitute new financial data or revenue guidance.
  • It reinforces the narrative established over the past 6 months regarding FDA clearance and commercial deployment, rather than introducing unexpected market-moving information.
  • No specific contract values or revenue commitments were disclosed alongside the award announcement.
  • The news aligns with previous expectations of technology validation but lacks the financial magnitude to be classified as a material game changer.
  • Given the company's history of equity-based debt settlements and small private placements, this serves primarily as marketing validation rather than a fundamental shift in capital structure or cash flow.
VPT · Price
Company Overview
  • Ventripoint Diagnostics Ltd. develops AI-powered cardiac imaging software (VMS+™).
  • Flagship Project: VMS+™ 4.0 converts standard 2D echocardiograms into volumetric 3D models with accuracy comparable to cardiac MRI.
  • Technology utilizes patented Knowledge-Based Reconstruction and artificial intelligence for point-of-care diagnostics.
  • Regulatory approvals include FDA clearance (Feb 2025), Health Canada licensing, and EU MDR certification.
  • Business model is shifting from equipment sales to a Device-as-a-Service subscription model to generate recurring revenue.
Read the original news release →

More from VentriPoint Diagnostics Ltd.